{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:15:40Z","timestamp":1793153740551,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"\n Importance<\/jats:title>\n Benzodiazepine use during pregnancy has raised significant concerns due to the potential harmful effects of this drug class on neonates. Studies on the association between benzodiazepine use and the risk of miscarriage are limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To quantify the risk of miscarriage associated with benzodiazepine use during pregnancy after controlling for unmeasured confounders and exposure time trends.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a nationwide, population-based case-time-control study using Taiwan\u2019s National Birth Certificate Application database and the National Health Insurance database. Pregnancies resulting in miscarriage between 2004 and 2018 were included in the case group and were 1:1 matched with exposure time-trend control individuals using disease risk score, considering demographic characteristics and prepregnancy comorbidities. Data were analyzed from August 2022 to March 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Discordant exposures to benzodiazepines during risk period (1-28 days before miscarriage) and 2 reference periods (31-58 days and 181-208 days before the last menstrual period) were compared for each pregnancy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Miscarriage was defined as any pregnancy loss occurring between the first prenatal care visit (usually 8 weeks) and the 19th completed week of pregnancy.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study comprised a total of 3\u202f067\u202f122 pregnancies among 1\u202f957\u202f601 women, 136\u202f134 of which (4.4%) resulted in miscarriage. The mean (SD) age of the study population was 30.61 (5.91) years. The use of benzodiazepines during pregnancy was associated with an increased risk of miscarriage (odds ratio [OR], 1.69; 95% CI, 1.52-1.87), and consistent findings were observed across multiple sensitivity analyses considering different time windows and accounting for misclassification. In subgroup analyses, an increased risk of miscarriage was associated with each commonly used individual benzodiazepine, ranging from case-time-control ORs of 1.39 (95% CI, 1.17-1.66) for alprazolam to 2.52 (95% CI, 1.89-3.36) for fludiazepam.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This nationwide case-time-control study revealed an increased risk of miscarriage associated with benzodiazepine use during pregnancy after accounting for measurable confounders, and results were unlikely to be due to unmeasured confounding. These findings underscore the necessity for health care professionals to meticulously balance the risk-benefit ratio when considering the use of benzodiazepines to treat psychiatric and sleep disorders during pregnancy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2023.4912","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T11:32:36Z","timestamp":1703676756000},"page":"366","source":"Crossref","is-referenced-by-count":34,"title":["Benzodiazepine Use During Pregnancy and Risk of Miscarriage"],"prefix":"10.1001","volume":"81","author":[{"given":"Lin-Chieh","family":"Meng","sequence":"first","affiliation":[{"name":"Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wan","family":"Lin","sequence":"additional","affiliation":[{"name":"Taiwan Drug Relief Foundation, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Chuang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Kung","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan"},{"name":"Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Taipei Municipal Gan-Dau Hospital (Managed by Taipei Veterans General Hospital), Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Yuan","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"School of Pharmacy, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"yoi230097r2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jad.2020.03.014","article-title":"Prevalence of benzodiazepines and benzodiazepine-related drugs exposure before, during and after pregnancy: A systematic review and meta-analysis.","volume":"269","author":"Bais","year":"2020","journal-title":"J Affect Disord"},{"issue":"1","key":"yoi230097r3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12884-021-03787-5","article-title":"Opioid and benzodiazepine dispensing and co-dispensing patterns among commercially insured pregnant women in the United States, 2007-2015.","volume":"21","author":"Qato","year":"2021","journal-title":"BMC Pregnancy Childbirth"},{"issue":"5","key":"yoi230097r4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2165\/00003495-198223050-00002","article-title":"Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.","volume":"23","author":"Kanto","year":"1982","journal-title":"Drugs"},{"issue":"1","key":"yoi230097r5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/jcp.v198:1","article-title":"Effects of peripheral benzodiazepine receptor ligands on proliferation and differentiation of human mesenchymal stem cells.","volume":"198","author":"Lee","year":"2004","journal-title":"J Cell Physiol"},{"issue":"8","key":"yoi230097r6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043462","article-title":"Live and non-live pregnancy outcomes among women with depression and anxiety: a population-based study.","volume":"7","author":"Ban","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"yoi230097r7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/0706743720904860","article-title":"Pregnancy and delivery outcomes following benzodiazepine exposure: a systematic review and meta-analysis.","volume":"65","author":"Grigoriadis","year":"2020","journal-title":"Can J Psychiatry"},{"key":"yoi230097r8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.854562","article-title":"Pregnancy and neonatal outcomes after exposure to alprazolam in pregnancy.","volume":"13","author":"Lee","year":"2022","journal-title":"Front Pharmacol"},{"issue":"9","key":"yoi230097r9","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jamapsychiatry.2019.0963","article-title":"Association between incident exposure to benzodiazepines in early pregnancy and risk of spontaneous abortion.","volume":"76","author":"Sheehy","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"yoi230097r10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19f13076","article-title":"Gestational exposure to benzodiazepines, 1: the risk of spontaneous abortion examined through the prism of research design.","volume":"80","author":"Andrade","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"yoi230097r11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/pds.v28.7","article-title":"Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy.","volume":"28","author":"Huybrechts","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"15","key":"yoi230097r12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jama.2017.3413","article-title":"Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit\/hyperactivity disorder in offspring.","volume":"317","author":"Sujan","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"yoi230097r13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamainternmed.2021.4571","article-title":"Association between prenatal exposure to antipsychotics and attention-deficit\/hyperactivity disorder, autism spectrum disorder, preterm birth, and small for gestational age.","volume":"181","author":"Wang","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"7","key":"yoi230097r14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S2215-0366(23)00148-7","article-title":"Association between maternal benzodiazepine or Z-hypnotic use in early pregnancy and the risk of stillbirth, preterm birth, and small for gestational age: a nationwide, population-based cohort study in Taiwan.","volume":"10","author":"Meng","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"yoi230097r15","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamainternmed.2015.3540","article-title":"Nationwide population science: lessons from the Taiwan National Health Insurance Research Database.","volume":"175","author":"Hsing","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"4","key":"yoi230097r16","first-page":"297","article-title":"Validation of the Taiwan Birth Registry using obstetric records.","volume":"103","author":"Lin","year":"2004","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"yoi230097r17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/00001648-199505000-00010","article-title":"The case-time-control design.","volume":"6","author":"Suissa","year":"1995","journal-title":"Epidemiology"},{"issue":"4","key":"yoi230097r18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/00001648-199807000-00016","article-title":"The case-time-control design: further assumptions and conditions.","volume":"9","author":"Suissa","year":"1998","journal-title":"Epidemiology"},{"issue":"2","key":"yoi230097r19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jval.2019.09.2746","article-title":"Comparison of different case-crossover variants in handling exposure-time trend or persistent-user bias: using dipeptidyl peptidase-4 inhibitors and the risk of heart failure as an example.","volume":"23","author":"Dong","year":"2020","journal-title":"Value Health"},{"issue":"10","key":"yoi230097r20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/pds.v23.10","article-title":"Trimethoprim use before pregnancy and risk of congenital malformation: reanalyzed using a case-crossover design and a case-time-control design.","volume":"23","author":"Sun","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"yoi230097r21","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/pds.v28.9","article-title":"Antidepressant use during pregnancy and risk of congenital heart defects: a case-time-control study.","volume":"28","author":"Sun","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"yoi230097r22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/aje\/kwg144","article-title":"Case-crossover and case-time-control designs in birth defects epidemiology.","volume":"158","author":"Hern\u00e1ndez-D\u00edaz","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"10","key":"yoi230097r23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/aje\/kwv302","article-title":"Comparison of calipers for matching on the disease risk score.","volume":"183","author":"Connolly","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"6","key":"yoi230097r24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jsr.2017.26.issue-6","article-title":"European guideline for the diagnosis and treatment of insomnia.","volume":"26","author":"Riemann","year":"2017","journal-title":"J Sleep Res"},{"issue":"Suppl 1","key":"yoi230097r25","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"3","key":"yoi230097r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.2639","article-title":"Early pregnancy loss management in the emergency department vs outpatient setting.","volume":"6","author":"Benson","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"yoi230097r27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003945","article-title":"First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: a population-based cohort study in South Korea.","volume":"19","author":"Noh","year":"2022","journal-title":"PLoS Med"},{"issue":"6","key":"yoi230097r29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/pds.v29.6","article-title":"Interrupted time series analysis to assess changes in prescription filling around conception and implications for exposure misclassification.","volume":"29","author":"Cohen","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"yoi230097r30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jclinepi.2011.09.004","article-title":"Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case-control designs.","volume":"65","author":"Nicholas","year":"2012","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"yoi230097r31","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/biom.13749","article-title":"A formal causal interpretation of the case-crossover design.","volume":"79","author":"Shahn","year":"2023","journal-title":"Biometrics"},{"issue":"2","key":"yoi230097r32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/EDE.0000000000001562","article-title":"Emulating a target trial of interventions initiated during pregnancy with healthcare databases: the example of COVID-19 vaccination.","volume":"34","author":"Hern\u00e1ndez-D\u00edaz","year":"2023","journal-title":"Epidemiology"},{"issue":"4","key":"yoi230097r33","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18r12412","article-title":"Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis.","volume":"80","author":"Grigoriadis","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi230097r34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000529141","article-title":"Maternal benzodiazepines and Z-drugs use during pregnancy and adverse birth and neurodevelopmental outcomes in offspring: a population-based cohort study.","volume":"92","author":"Chan","year":"2023","journal-title":"Psychother Psychosom"},{"issue":"11","key":"yoi230097r35","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1111\/aogs.v99.11","article-title":"Pregnancy loss: a 40-year nationwide assessment.","volume":"99","author":"Lidegaard","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"key":"yoi230097r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112993","article-title":"Prescription patterns of benzodiazepine and benzodiazepine-related drugs in the peripartum period: a population-based study.","volume":"288","author":"Bais","year":"2020","journal-title":"Psychiatry Res"},{"key":"yoi230097r1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-642-54562-7_7","volume-title":"Psychopharmacology and Pregnancy: Treatment Efficacy, Risks, and Guidelines","author":"Gentile","year":"2014"},{"key":"yoi230097r28","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2022. Accessed 8 April, 2023. https:\/\/www.whocc.no\/atc_ddd_index_and_guidelines\/guidelines\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2813434\/jamapsychiatry_meng_2023_oi_230097_1711140333.67354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T11:26:49Z","timestamp":1712143609000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2813434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4912","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}